A panel of experts has released a series of recommendations for carers of children with chronic conditions, such as…
Articles by Joana Carvalho, PhD
Vertex Pharmaceuticals announced that a reimbursement program covering Orkambi (lumacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor combo) will be opening for…
Zikani Therapeutics has raised $7.5 million in Series A funding to advance work, using its TURBO-ZM technology…
Enrollment is continuing in a Phase 1/2 trial testing the safety and properties of AR-501, a potential inhalation treatment for chronic…
Savara Pharmaceuticals has stopped patient enrollment into two of its ongoing clinical trials in cystic fibrosis (CF) patients…
Tiny particles, or nanoparticles, work better as transport and delivery vehicles for the RNA molecules central to some forms of…
Cystic Fibrosis News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other important events related…
A triple combination of dirocaftor (PTI-808), Proteostasis Therapeutics’ investigational CFTR potentiator, with a proprietary CFTR amplifier…
The therapeutic triple combo elexacaftor (VX-445), tezacaftor, and ivacaftor leads to marked improvements in lung function and quality of…
Researchers have discovered a stress response mechanism that allows Pseudomonas aeruginosa, a bacteria highly resistant to antibiotics that…